XML 19 R6.htm IDEA: XBRL DOCUMENT v3.25.3
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Cash flows from operating activities:    
Net loss $ (9,783,000) $ (11,353,000)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation of property and equipment 28,000 28,000
Abandonment and expiration of patents and trademark rights 697,000 46,000
Amortization of patent, trademark rights 139,000 154,000
Non-cash lease expense 140,000 226,000
Equity-based compensation 60,000 490,000
Gain on sale of marketable securities (17,000) (95,000)
Amortization of financial obligation 252,000 232,000
Gain on fair value of warrants (670,000)
Loss on issuance of warrants 3,977,000 458,000
Non-cash gain on settlement of liability (3,041,000)  
Change in assets and liabilities:    
Funds receivable from New Jersey net operating loss 1,181,000
Prepaid expenses and other current assets 33,000 (63,000)
Lease liability (134,000) (231,000)
Other assets 750,000 (1,028,000)
Accounts payable (1,656,000) (179,000)
Accrued expenses 254,000 (799,000)
Net cash used in operating activities (8,971,000) (10,933,000)
Cash flows from investing activities:    
Proceeds from sale of marketable securities 2,322,000 1,597,000
Purchase of marketable securities (91,000) (158,000)
Purchase of property and equipment (18,000)
(Purchase) abandonment of patent and trademark rights (283,000) (419,000)
Net cash provided by investing activities 1,948,000 1,002,000
Cash flows from financing activities:    
Proceeds from issuance of common stock and warrants 7,314,000
Proceeds from sale of stock, net of issuance costs 367,000 860,000
Proceeds from note payable, net of issuance costs 250,000 2,500,000
Repayment of debt with cash (660,000)
Proceeds from equity line of credit 398,000 2,047,000
Net cash provided by financing activities 7,669,000 5,407,000
Net increase (decrease) in cash and cash equivalents 646,000 (4,524,000)
Cash and cash equivalents at beginning of period 1,701,000 5,439,000
Cash and cash equivalents at end of period 2,347,000 915,000
Supplemental disclosures of non-cash investing and financing cash flow information:    
Operating lease-Right of Use Assets (42,000) (3,000)
Unrealized gain on marketable securities 73,000 373,000
Repayment of debt obligation with shares $ 450,000 $ 175,000